This clinical trial is focused on studying a type of lung cancer known as Metastatic Non-Small Cell Lung Cancer (NSCLC). This is a condition where cancer cells from the lung have spread to other parts of the body. The study is comparing two treatments: a new drug called ONC-392 and a standard chemotherapy drug known as Docetaxel. ONC-392 is a special type of protein called a humanised IgG1 monoclonal antibody that targets a specific part of the immune system, while Docetaxel is a chemical used to kill cancer cells.
The purpose of this study is to see how well ONC-392 works compared to Docetaxel in patients whose cancer has continued to grow despite previous treatments with other cancer drugs called PD-1/PD-L1 inhibitors. These inhibitors are a type of immunotherapy that helps the immune system fight cancer. The study will involve patients receiving either ONC-392 or Docetaxel, and their health will be monitored over a period of time to see which treatment helps them live longer.
Participants in the study will receive their assigned treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will last up to 52 weeks, during which time doctors will check the patients’ response to the treatment and any side effects they might experience. The main goal is to determine which treatment is more effective in improving the overall survival of patients with this type of lung cancer.
Belgium 
Germany 
Italy 
Spain 
The Netherlands 
